ArticleFrontiers in neurology2024
Temporary trigeminal ganglion stimulation can improve zoster-related trigeminal neuralgia: a retrospective study in a single center.
Article in Frontiers in neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Conventional management approaches have been challenged in dealing with zoster-related trigeminal neuralgia. Percutaneous trigeminal ganglion stimulation (TGS) has been rarely reported as a potential treatment option for alleviating pain associated with this condition. The present study investigated the application of percutaneous TGS in a series of patients suffering from Zoster-related trigeminal neuralgia to evaluate its potential efficacy of pain relief. Methods: We retrospectively reviewed the medical records of all patients who underwent TGS at the Department of Pain Management, Second Affiliated Hospital of Guangxi Medical University. All patients were followed for up to 6 months. Clinical data, including the Visual Analog Scale (VAS), Pittsburgh Sleep Quality Index (PSQI), and medication consumption were recorded before and after treatment. Adverse events related to the treatment were also documented. Results: A total of nine patients underwent percutaneous TGS for Zoster-related trigeminal neuralgia. Among these patients, five (56%) experienced more than 50% pain relief at discharge. At the six-month follow-up, the mean VAS score decreased from preoperative 6.1 ± 1.5 to 2.5 ± 1.9, demonstrating a statistically significant reduction ( Discussion: The results of the present study suggest that this contributes growing evidence that percutaneous TGS may be an effective treatment for Zoster - related trigeminal neuralgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.